Recent Updates
Recently added Catalysts
ONC Positive Sentiment

Samenvatting: BeOne Medicines kondigt nieuwe overlevingsgegevens uit Fase 3-studie aan die het voordeel bevestigen van behandelregimes met ZIIHERA bij eerstelijnsbehandeling van HER2-positieve gastro-oesofageale kanker

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines announced positive interim results from the Phase 3 HERIZON-GEA-01 study. The study evaluated ZIIHERA in combination with chemotherapy, with or without TEVIMBRA, for first-line treatment of HER2-positive gastro-esophageal cancer. These results confirm the treatment's benefits for patients with advanced or metastatic disease.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive interim results from Phase 3 study HERIZON-GEA-01.
  • ZIIHERA shows benefits in first-line treatment for HER2-positive cancer.
  • Combination therapy with TEVIMBRA enhances treatment efficacy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
Tislelizumab
Phase 3 · Non-small Cell Lung Cancer

Full Press Release Details

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een wereldwijd oncologiebedrijf, heeft vandaag positieve hoofdresultaten bekendgemaakt van de tweede tussentijdse analyse (IA2) van de Fase 3-studie HERIZON-GEA-01. In deze studie wordt ZIIHERA® (zanidatamab) onderzocht in combinatie met chemotherapie, al dan niet aangevuld met TEVIMBRA® (tislelizumab), als eerstelijnsbehandeling voor HER2-positief, lokaal gevorderd of gemetastaseerd gastro-oesofa

Frequently Asked Questions

What are the main results of the HERIZON-GEA-01 study?

The study reported positive interim results for ZIIHERA as a treatment.

What is ZIIHERA used for?

ZIIHERA is used in first-line treatment for HER2-positive gastro-esophageal cancer.

What combination therapies were tested in the study?

ZIIHERA was tested with chemotherapy and optionally with TEVIMBRA.

Who conducted the HERIZON-GEA-01 study?

The study was conducted by BeOne Medicines Ltd.

ShareAdd on Google
Tags: ONC Viatris Investor Conferences Healthcare BeOne Medicines ZIIHERA HER2-positive gastro-esophageal cancer Phase 3 study
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
TislelizumabPhase 3
Non-small Cell Lung Cancer →

Catalyst track record

+15%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →